Breaking Finance News

Catalent Inc (NASDAQ:CTLT) has been upgraded to B- in a report by TheStreet today.

TheStreet has upgraded Catalent Inc (NASDAQ:CTLT) to B- in a report released on Wednesday April 19, 2017.

Previously on Thursday April 20, 2017, Zacks Investment Research reported about Catalent Inc (NASDAQ:CTLT) raised the target price from $0.00 to $31.00. At the time, this indicated a possible upside of 0.10%.

Just yesterday Catalent Inc (NASDAQ:CTLT) traded 1.40% higher at $28.07. Catalent Inc’s 50-day moving average is $28.38 and its 200-day moving average is $26.53. The last stock price is up 6.64% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has increased 0.03% over the same time period. 386,852 shares of the stock traded hands, down from an average trading volume of 644,139

See Chart Below

Catalent Inc (NASDAQ:CTLT)

Catalent Inc has a 52 week low of $20.94 and a 52 week high of $30.28 with a P/E ratio of 39.35 The company’s market cap is currently $0.

In addition to TheStreet reporting its stock price target, a total of 6 brokers have issued a research note on the company. The average stock price target is $27.92 with 0 brokers rating the stock a strong buy, 0 brokers rating the stock a buy, 0 brokers rating the stock a hold, 0 brokers rating the stock a underperform, and finally 0 brokers rating the stock a sell.

General Information About Catalent Inc (NASDAQ:CTLT)

Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.